23-10-2012

Carefully applying electricity to the brain can reduce tremors and involuntary movements associated with Parkinson’s disease and a wide range of other conditions, and now a new compilation of major research findings and clinical recommendations is available to help guide referring physicians ...

more

New collaboration to develop research in immunology and neurology

20-03-2012

UCB Pharma and Oxford University agreed to collaborate on cutting-edge pharmaceutical research projects, enabling scientists from industry and academia to work together to develop medicines to treat serious diseases in immunology and neurology. These combined resources and expertise will give ...

more

First-ever feat provides new method to understand cause of disease, develop drugs

27-01-2012

Led by researchers at the University of California, San Diego School of Medicine, scientists have, for the first time, created stem cell-derived, in vitro models of sporadic and hereditary Alzheimer's disease (AD), using induced pluripotent stem cells from patients with the much-dreaded ...

more

Hybrigenics will receive EUR four million over three years to identify new deubiquitinating enzymes and screen their inhibitors, and is further eligible to success milestones

11-10-2011

Hybrigenics and Servier announced that they have signed a licence and research collaboration agreement in the field of deubiquitinating enzymes (DUBs) applied to oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases.Hybrigenics will identify and ...

more

02-12-2010

Allon Therapeutics Inc. announced it has received a major grant from the Michael J. Fox Foundation (MJFF) for Parkinson’s Research to conduct pre-clinical research that will help determine the potential of the Company’s lead neuroprotective drug, davunetide, as a treatment for Parkinson’s ...

more

Julia Lloyd-Parks and Mark Watling join the organisation as Senior Partners

23-11-2010

TranScrip Partners LLP announced the appointment of two new senior partners, Julia Lloyd-Parks and Mark Watling. The move is set to further enhance the organisation’s high level expertise in clinical research, clinical development and medical affairs across multiple therapeutic areas. This ...

more

01-11-2010

NEUROKIN announced the appointment of Mr. Bernard Reculeau as a new member of the Board of Directors, and the arrival of Mr. Jesús Benavides within the company’s Scientific Committee. Bernard has over 25 years of experience in leadership positions in the pharmaceutical industry. At Rhone ...

more

TERACLES is the First Phase III Study of an Oral Drug as an Add-On to Standard Therapy in Relapsing Multiple Sclerosis

28-10-2010

Sanofi-aventis announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple sclerosis (RMS) treated with interferon beta (IFN beta). Teriflunomide ...

more

26-08-2010

Production of new nerve cells in the human brain is linked to learning and memory, according to a new study from the University of Florida. The research is the first to show such a link in humans. The findings, published in the journal Brain, provide clues about processes involved in age- and ...

more

17-08-2010

A team of researchers has discovered new evidence that Parkinson's disease may have an infectious or autoimmune origin. "Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease" appears in Nature Genetics. The study was conducted by the ...

more